International Journal of Hematology

, Volume 78, Issue 2, pp 163–167

L-Asparaginase—Based Regimen in the Treatment of Refractory Midline Nasal/Nasal-Type T/NK-Cell Lymphoma

  • Weiben Yong
  • Wen Zheng
  • Yuntao Zhang
  • Jun Zhu
  • Yan Wei
  • Deliang Zhu
  • Jiyou Li
Article

DOI: 10.1007/BF02983387

Cite this article as:
Yong, W., Zheng, W., Zhang, Y. et al. Int J Hematol (2003) 78: 163. doi:10.1007/BF02983387

Abstract

Nasal, nasal-type T-cell/natural killer cell (T/NK-cell) lymphoma is a rare disease, and its prognosis is poor. Between March 1992 and March 2002 we investigated a new L-asparaginase-based salvage regimen to treat the disease and improve response to treatment and 5-year overall survival rate. Eighteen patients with refractory midline nasal, nasal-type T/NK-cell lymphoma, who were resistant to a cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP)-like regimen, received an L-asparaginase—based salvage regimen (L-asparaginase, vincristine, and dexamethasone). Primary involved field radiation was given to the patients after chemotherapy.Ten (55.6%) of the patients achieved complete response (CR). Five patients (27.8%) achieved partial response (PR).The overall response rate (CR + PR) was 83.3%.The 5-year overall survival rate was 55.6%. Results of the preliminary clinical study indicated that the L-asparaginase—based salvage regimen significantly improved the response rate and 5-year survival rate.The findings suggested that the therapy is a promising new salvage regimen for treating refractory midline nasal, nasal-type T/NK-cell lymphoma. Int J Hematol. 2003;78:163-167.

Key words

L-asparaginase Treatment T/NK-cell lymphoma 

Copyright information

© The Japanese Society of Hematology 2003

Authors and Affiliations

  • Weiben Yong
    • 1
  • Wen Zheng
    • 1
  • Yuntao Zhang
    • 1
  • Jun Zhu
    • 1
  • Yan Wei
    • 1
  • Deliang Zhu
    • 1
  • Jiyou Li
    • 2
  1. 1.Department of Oncology Beijing Cancer Hospital The School of OncologyPeking UniversityBeijingPR China
  2. 2.Pathology, Beijing Cancer Hospital, School of OncologyPeking UniversityBeijingPeople’s Republic of China

Personalised recommendations